Early Local Therapy Survival Benefit Refuted For De Novo Metastatic Breast Cancer
For women with de novo metastatic breast cancer, early locoregional therapy does not improve overall survival
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
For women with de novo metastatic breast cancer, early locoregional therapy does not improve overall survival
The selective MET inhibitor tepotinib could benefit up to half of patients with advanced or metastatic non-small-cell lung cancer with a MET exon 14 skipping mutation
A dual checkpoint inhibitor regimen may be feasible for patients with previously treated advanced colorectal cancer
Combining pembrolizumab with a novel innate immune activator shows early potential for the treatment of metastatic triple-negative breast cancer
Advanced non-small-cell lung cancer with a MET exon 14 skipping mutation may respond to capmatinib therapy
Durvalumab appears to have clinical activity in the recurrent or metastatic head and neck squamous cell carcinoma setting, despite the lack of a significant survival benefit over standard of care
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.